{"transactions":[{"id":743655,"issuer":{"id":7338,"kind":"organization","name":"CervoMed Inc."},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-10T23:43:53.000Z","date":"2026-06-08","kind":"grant","planned":false,"acquired":true,"shares":8150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On June 8, 2026, in connection with the Reporting Person's election to the Issuer's board of directors at its 2026 Annual Meeting of Stockholders, the Reporting Person was granted an option to purchase 8,150 shares of the Issuer's common stock under the Issuer's 2025 Equity Incentive Plan in accordance with the terms of the Issuer's non-employee director compensation policy. The shares of common stock underlying the award will vest on a monthly basis over a one-year period in substantially equal 1/12th increments on the last day of each month beginning on June 30, 2026, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":8150,"derivative":{"exercise_price":2.91,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":8150},"source":{"system":"sec-edgar","filing":"0001437749-26-020214","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1053691/000143774926020214/rdgdoc.xml","form_type":"4"}},{"id":856423,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-06T21:12:42.000Z","date":"2026-03-04","kind":"sale","planned":false,"acquired":false,"shares":223,"price":325.67,"value":72624.41,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $325.40 to $326.21. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":61805,"source":{"system":"sec-edgar","filing":"0001735276-26-000061","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000061/edgardoc.xml","form_type":"4"}},{"id":856422,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-06T21:12:42.000Z","date":"2026-03-04","kind":"sale","planned":false,"acquired":false,"shares":291,"price":324.88,"value":94540.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.39 to $325.38. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":62028,"source":{"system":"sec-edgar","filing":"0001735276-26-000061","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000061/edgardoc.xml","form_type":"4"}},{"id":856421,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-06T21:12:42.000Z","date":"2026-03-04","kind":"sale","planned":false,"acquired":false,"shares":818,"price":323.84,"value":264901.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $323.38 to $324.35. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":62319,"source":{"system":"sec-edgar","filing":"0001735276-26-000061","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000061/edgardoc.xml","form_type":"4"}},{"id":856420,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-06T21:12:42.000Z","date":"2026-03-04","kind":"sale","planned":false,"acquired":false,"shares":374,"price":323.01,"value":120805.74,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $322.36 to $323.36. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":63137,"source":{"system":"sec-edgar","filing":"0001735276-26-000061","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000061/edgardoc.xml","form_type":"4"}},{"id":856419,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-06T21:12:42.000Z","date":"2026-03-04","kind":"sale","planned":false,"acquired":false,"shares":309,"price":321.82,"value":99442.38,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $321.34 to $322.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":63511,"source":{"system":"sec-edgar","filing":"0001735276-26-000061","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000061/edgardoc.xml","form_type":"4"}},{"id":856418,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-06T21:12:42.000Z","date":"2026-03-04","kind":"sale","planned":false,"acquired":false,"shares":230,"price":320.81,"value":73786.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $320.33 to $321.33. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":63820,"source":{"system":"sec-edgar","filing":"0001735276-26-000061","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000061/edgardoc.xml","form_type":"4"}},{"id":856417,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-06T21:12:42.000Z","date":"2026-03-04","kind":"sale","planned":false,"acquired":false,"shares":109,"price":320.01,"value":34881.09,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $319.28 to $320.28. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":64050,"source":{"system":"sec-edgar","filing":"0001735276-26-000061","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000061/edgardoc.xml","form_type":"4"}},{"id":856416,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-06T21:12:42.000Z","date":"2026-03-04","kind":"sale","planned":false,"acquired":false,"shares":114,"price":319.03,"value":36369.42,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $318.27 to $319.27. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":64159,"source":{"system":"sec-edgar","filing":"0001735276-26-000061","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000061/edgardoc.xml","form_type":"4"}},{"id":862502,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Stock Option  (right to buy)","published_at":"2026-03-05T00:31:44.000Z","date":"2026-03-02","kind":"grant","planned":false,"acquired":true,"shares":10480,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F14","text":"The stock option vests as to 25% of the shares on the first anniversary of the grant date and the remaining shares vest in equal installments at the end of each successive three-month period thereafter until the fourth anniversary of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date."}],"balance_after":10480,"derivative":{"exercise_price":325.07,"expiration_date":"2036-03-02","underlying":"Common Stock","underlying_shares":10480},"source":{"system":"sec-edgar","filing":"0001735276-26-000053","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000053/edgardoc.xml","form_type":"4"}},{"id":862501,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-05T00:31:44.000Z","date":"2026-03-02","kind":"sale","planned":false,"acquired":false,"shares":53,"price":332.64,"value":17629.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $332.34 to $332.24. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":64273,"source":{"system":"sec-edgar","filing":"0001735276-26-000053","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000053/edgardoc.xml","form_type":"4"}},{"id":862500,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-05T00:31:44.000Z","date":"2026-03-02","kind":"sale","planned":false,"acquired":false,"shares":129,"price":331.93,"value":42818.97,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $331.32 to $332.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":64326,"source":{"system":"sec-edgar","filing":"0001735276-26-000053","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000053/edgardoc.xml","form_type":"4"}},{"id":862499,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-05T00:31:44.000Z","date":"2026-03-02","kind":"sale","planned":false,"acquired":false,"shares":112,"price":330.85,"value":37055.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $330.30 to $331.30. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":64455,"source":{"system":"sec-edgar","filing":"0001735276-26-000053","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000053/edgardoc.xml","form_type":"4"}},{"id":862498,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-05T00:31:44.000Z","date":"2026-03-02","kind":"sale","planned":false,"acquired":false,"shares":234,"price":329.71,"value":77152.14,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $329.29 to $330.29. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":64567,"source":{"system":"sec-edgar","filing":"0001735276-26-000053","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000053/edgardoc.xml","form_type":"4"}},{"id":862497,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-05T00:31:44.000Z","date":"2026-03-02","kind":"sale","planned":false,"acquired":false,"shares":138,"price":328.71,"value":45361.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $328.28 to $329.26. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":64801,"source":{"system":"sec-edgar","filing":"0001735276-26-000053","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000053/edgardoc.xml","form_type":"4"}},{"id":862496,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-05T00:31:44.000Z","date":"2026-03-02","kind":"sale","planned":false,"acquired":false,"shares":454,"price":327.67,"value":148762.18,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $327.24 to $328.24. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":64939,"source":{"system":"sec-edgar","filing":"0001735276-26-000053","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000053/edgardoc.xml","form_type":"4"}},{"id":862495,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-05T00:31:44.000Z","date":"2026-03-02","kind":"sale","planned":false,"acquired":false,"shares":541,"price":326.81,"value":176804.21,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $326.23 to $327.23. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":65393,"source":{"system":"sec-edgar","filing":"0001735276-26-000053","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000053/edgardoc.xml","form_type":"4"}},{"id":862494,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-05T00:31:44.000Z","date":"2026-03-02","kind":"sale","planned":false,"acquired":false,"shares":356,"price":325.63,"value":115924.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $325.21 to $326.21. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":65934,"source":{"system":"sec-edgar","filing":"0001735276-26-000053","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000053/edgardoc.xml","form_type":"4"}},{"id":862493,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-05T00:31:44.000Z","date":"2026-03-02","kind":"sale","planned":false,"acquired":false,"shares":124,"price":324.65,"value":40256.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.20 to $325.20. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":66290,"source":{"system":"sec-edgar","filing":"0001735276-26-000053","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000053/edgardoc.xml","form_type":"4"}},{"id":862492,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-05T00:31:44.000Z","date":"2026-03-02","kind":"sale","planned":false,"acquired":false,"shares":65,"price":323.62,"value":21035.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $323.16 to $324.15. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":66414,"source":{"system":"sec-edgar","filing":"0001735276-26-000053","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000053/edgardoc.xml","form_type":"4"}},{"id":862491,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-05T00:31:44.000Z","date":"2026-03-02","kind":"grant","planned":false,"acquired":true,"shares":4769,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest over a three-year period, with one third vesting on each of the first, second and third anniversaries of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date."}],"balance_after":66479,"source":{"system":"sec-edgar","filing":"0001735276-26-000053","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000053/edgardoc.xml","form_type":"4"}},{"id":874876,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-03-02T21:09:41.000Z","date":"2026-02-27","kind":"exercise","planned":false,"acquired":false,"shares":1908,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"These shares are represented by restricted stock units (RSUs) granted under the Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On February 27, 2023, the reporting person was granted 5,724 restricted stock units that vest ratably on each of the first, second and third anniversaries of the Grant Date.  On February 27, 2026, the third and final tranche of restricted stock units from the February 27, 2023 grant vested and was released, as reported on this Form 4."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units vest ratably in three installments, with one third vesting on each of the first, second and third anniversaries of the grant date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1908},"source":{"system":"sec-edgar","filing":"0001735276-26-000040","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000040/edgardoc.xml","form_type":"4"}},{"id":874875,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-02T21:09:41.000Z","date":"2026-02-27","kind":"exercise","planned":false,"acquired":true,"shares":1908,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":61710,"source":{"system":"sec-edgar","filing":"0001735276-26-000040","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000040/edgardoc.xml","form_type":"4"}},{"id":901558,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-18T00:26:01.000Z","date":"2026-02-13","kind":"sale","planned":false,"acquired":false,"shares":2242,"price":310.0808,"value":695201.1536,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $302.55 to $314.60. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":59802,"source":{"system":"sec-edgar","filing":"0001735276-26-000025","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000025/edgardoc.xml","form_type":"4"}},{"id":901557,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-18T00:26:01.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":4579,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 27, 2023, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of forty (40) percent of the shares subject to the PSU based on the issuer publicly reporting the achievement of non-GAAP operating income for fiscal year 2025 on February 12, 2026, as determined by the People, Culture and Compensation Committee of the Issuer Board of Directors."}],"balance_after":62044,"source":{"system":"sec-edgar","filing":"0001735276-26-000025","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000025/edgardoc.xml","form_type":"4"}},{"id":939436,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-14T21:22:39.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":27,"price":377.82,"value":10201.14,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."}],"balance_after":57465,"source":{"system":"sec-edgar","filing":"0001735276-26-000013","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000013/edgardoc.xml","form_type":"4"}},{"id":939435,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-14T21:22:39.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":34,"price":375.65,"value":12772.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."}],"balance_after":57492,"source":{"system":"sec-edgar","filing":"0001735276-26-000013","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000013/edgardoc.xml","form_type":"4"}},{"id":939434,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-14T21:22:39.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":25,"price":374.44,"value":9361.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F21","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $374.08 to $374.89. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":57526,"source":{"system":"sec-edgar","filing":"0001735276-26-000013","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000013/edgardoc.xml","form_type":"4"}},{"id":939433,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-14T21:22:39.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":6,"price":372.46,"value":2234.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F20","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $372.35 to $372.50. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":57551,"source":{"system":"sec-edgar","filing":"0001735276-26-000013","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000013/edgardoc.xml","form_type":"4"}},{"id":939432,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-14T21:22:39.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":36,"price":370.87,"value":13351.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F19","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $370.43 to $371.23. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":57557,"source":{"system":"sec-edgar","filing":"0001735276-26-000013","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000013/edgardoc.xml","form_type":"4"}},{"id":939431,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-14T21:22:39.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":73,"price":369.48,"value":26972.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F18","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $369.13 to $369.93. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":57593,"source":{"system":"sec-edgar","filing":"0001735276-26-000013","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000013/edgardoc.xml","form_type":"4"}},{"id":939430,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-14T21:22:39.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":170,"price":368.62,"value":62665.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F17","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $368.09 to $369.08. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":57666,"source":{"system":"sec-edgar","filing":"0001735276-26-000013","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000013/edgardoc.xml","form_type":"4"}},{"id":939429,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-14T21:22:39.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":76,"price":367.4,"value":27922.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F16","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $367.04 to $368.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":57836,"source":{"system":"sec-edgar","filing":"0001735276-26-000013","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000013/edgardoc.xml","form_type":"4"}},{"id":939428,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-14T21:22:39.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":92,"price":366.41,"value":33709.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F15","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $366.03 to $366.96. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":57912,"source":{"system":"sec-edgar","filing":"0001735276-26-000013","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000013/edgardoc.xml","form_type":"4"}},{"id":939427,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-14T21:22:39.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":405,"price":365.56,"value":148051.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F14","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $365.01 to $366.01. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":58004,"source":{"system":"sec-edgar","filing":"0001735276-26-000013","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000013/edgardoc.xml","form_type":"4"}},{"id":939426,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-14T21:22:39.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":365,"price":364.83,"value":133162.95,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $364.00 to $365.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":58409,"source":{"system":"sec-edgar","filing":"0001735276-26-000013","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000013/edgardoc.xml","form_type":"4"}},{"id":939425,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-14T21:22:39.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":87,"price":363.55,"value":31628.85,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $362.99 to $363.99. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":58774,"source":{"system":"sec-edgar","filing":"0001735276-26-000013","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000013/edgardoc.xml","form_type":"4"}},{"id":939424,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-14T21:22:39.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":135,"price":362.38,"value":48921.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $361.93 to $362.92. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":58861,"source":{"system":"sec-edgar","filing":"0001735276-26-000013","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000013/edgardoc.xml","form_type":"4"}},{"id":939423,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-14T21:22:39.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":181,"price":361.45,"value":65422.45,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $360.90 to $361.89. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":58996,"source":{"system":"sec-edgar","filing":"0001735276-26-000013","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000013/edgardoc.xml","form_type":"4"}},{"id":939422,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-14T21:22:39.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":284,"price":360.22,"value":102302.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $359.79 to $360.79. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":59177,"source":{"system":"sec-edgar","filing":"0001735276-26-000013","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000013/edgardoc.xml","form_type":"4"}},{"id":939421,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-14T21:22:39.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":156,"price":359.14,"value":56025.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $358.69 to $359.66. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":59461,"source":{"system":"sec-edgar","filing":"0001735276-26-000013","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000013/edgardoc.xml","form_type":"4"}},{"id":939420,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-14T21:22:39.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":226,"price":358.18,"value":80948.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $357.68 to $358.68. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":59617,"source":{"system":"sec-edgar","filing":"0001735276-26-000013","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000013/edgardoc.xml","form_type":"4"}},{"id":939419,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-14T21:22:39.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":176,"price":357.17,"value":62861.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $356.63 to $357.63. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":59843,"source":{"system":"sec-edgar","filing":"0001735276-26-000013","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000013/edgardoc.xml","form_type":"4"}},{"id":939418,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-14T21:22:39.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":76,"price":356.09,"value":27062.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $356.62 to $356.61. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":60019,"source":{"system":"sec-edgar","filing":"0001735276-26-000013","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000013/edgardoc.xml","form_type":"4"}},{"id":939417,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-14T21:22:39.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":78,"price":355.16,"value":27702.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $354.54 to $355.53. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":60095,"source":{"system":"sec-edgar","filing":"0001735276-26-000013","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000013/edgardoc.xml","form_type":"4"}},{"id":939416,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-14T21:22:39.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":72,"price":353.95,"value":25484.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $353.53 to $354.41. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":60173,"source":{"system":"sec-edgar","filing":"0001735276-26-000013","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000013/edgardoc.xml","form_type":"4"}},{"id":939415,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-14T21:22:39.000Z","date":"2026-01-11","kind":"grant","planned":false,"acquired":true,"shares":6193,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 1, 2024, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of forty (40) percent of the shares subject to the PSU based on the issuer publicly reporting $2.5 billion in annual net product revenue in accordance with GAAP, as determined by the People, Culture and Compensation Committee of the Issuer Board of Directors on January 11, 2026."}],"balance_after":60245,"source":{"system":"sec-edgar","filing":"0001735276-26-000013","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000013/edgardoc.xml","form_type":"4"}},{"id":1025190,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-10-03T21:14:56.000Z","date":"2025-10-02","kind":"sale","planned":false,"acquired":false,"shares":4,"price":457.64,"value":1830.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024."}],"balance_after":54052,"source":{"system":"sec-edgar","filing":"0001735276-25-000117","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000117/edgardoc.xml","form_type":"4"}},{"id":1025189,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-10-03T21:14:56.000Z","date":"2025-10-02","kind":"sale","planned":false,"acquired":false,"shares":191,"price":457.43,"value":87369.13,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024."}],"balance_after":54056,"source":{"system":"sec-edgar","filing":"0001735276-25-000117","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000117/edgardoc.xml","form_type":"4"}},{"id":1025188,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-10-03T21:14:56.000Z","date":"2025-10-02","kind":"sale","planned":false,"acquired":false,"shares":95,"price":455.82,"value":43302.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $455.42 to $456.09. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":54247,"source":{"system":"sec-edgar","filing":"0001735276-25-000117","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000117/edgardoc.xml","form_type":"4"}},{"id":1025187,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-10-03T21:14:56.000Z","date":"2025-10-02","kind":"sale","planned":false,"acquired":false,"shares":317,"price":454.84,"value":144184.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $454.38 to $455.34. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":54342,"source":{"system":"sec-edgar","filing":"0001735276-25-000117","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000117/edgardoc.xml","form_type":"4"}},{"id":1025186,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-10-03T21:14:56.000Z","date":"2025-10-02","kind":"sale","planned":false,"acquired":false,"shares":428,"price":453.77,"value":194213.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $453.37 to $454.37. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":54659,"source":{"system":"sec-edgar","filing":"0001735276-25-000117","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000117/edgardoc.xml","form_type":"4"}},{"id":1025185,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-10-03T21:14:56.000Z","date":"2025-10-02","kind":"sale","planned":false,"acquired":false,"shares":869,"price":452.69,"value":393387.61,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $452.33 to $453.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":55087,"source":{"system":"sec-edgar","filing":"0001735276-25-000117","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000117/edgardoc.xml","form_type":"4"}},{"id":1025184,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-10-03T21:14:56.000Z","date":"2025-10-02","kind":"sale","planned":false,"acquired":false,"shares":432,"price":451.86,"value":195203.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $451.31 to $452.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":55956,"source":{"system":"sec-edgar","filing":"0001735276-25-000117","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000117/edgardoc.xml","form_type":"4"}},{"id":1025183,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-10-03T21:14:56.000Z","date":"2025-10-02","kind":"sale","planned":false,"acquired":false,"shares":704,"price":450.81,"value":317370.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $450.29 to $451.29. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":56388,"source":{"system":"sec-edgar","filing":"0001735276-25-000117","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000117/edgardoc.xml","form_type":"4"}},{"id":1025182,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-10-03T21:14:56.000Z","date":"2025-10-02","kind":"sale","planned":false,"acquired":false,"shares":324,"price":449.79,"value":145731.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $449.26 to $450.26. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":57092,"source":{"system":"sec-edgar","filing":"0001735276-25-000117","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000117/edgardoc.xml","form_type":"4"}},{"id":1025181,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-10-03T21:14:56.000Z","date":"2025-10-02","kind":"sale","planned":false,"acquired":false,"shares":234,"price":448.77,"value":105012.18,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $448.25 to $449.24. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":57416,"source":{"system":"sec-edgar","filing":"0001735276-25-000117","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000117/edgardoc.xml","form_type":"4"}},{"id":1025180,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-10-03T21:14:56.000Z","date":"2025-10-02","kind":"sale","planned":false,"acquired":false,"shares":73,"price":447.92,"value":32698.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $447.21 to $448.21. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":57650,"source":{"system":"sec-edgar","filing":"0001735276-25-000117","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000117/edgardoc.xml","form_type":"4"}},{"id":1025179,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-10-03T21:14:56.000Z","date":"2025-10-02","kind":"sale","planned":false,"acquired":false,"shares":150,"price":446.53,"value":66979.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $446.19 to $447.19. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":57723,"source":{"system":"sec-edgar","filing":"0001735276-25-000117","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000117/edgardoc.xml","form_type":"4"}},{"id":1025178,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-10-03T21:14:56.000Z","date":"2025-10-01","kind":"grant","planned":false,"acquired":true,"shares":4644,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On March 1, 2024, the reporting person was granted a PSU under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of thirty (30) percent of the shares subject to the PSU based on the issuer publicly reporting the initiation of a Phase 3 clinical study in a prevalent indication, as determined by the PC&C Committee on October 1, 2025."}],"balance_after":57873,"source":{"system":"sec-edgar","filing":"0001735276-25-000117","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000117/edgardoc.xml","form_type":"4"}},{"id":1025177,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-10-03T21:14:56.000Z","date":"2025-10-01","kind":"grant","planned":false,"acquired":true,"shares":3108,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 24, 2021, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of four specified performance measures. The shares reported were issued to the reporting person upon vesting of one-quarter of the shares subject to the PSU based on the issuer publicly reporting the initiation of a Phase 3 clinical study of an RNAi therapeutic in development to treat a prevalent disease, as determined by the People, Culture and Compensation (PC&C) Committee of the Issuer Board of Directors on October 1, 2025."}],"balance_after":53229,"source":{"system":"sec-edgar","filing":"0001735276-25-000117","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000117/edgardoc.xml","form_type":"4"}},{"id":1062586,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-08-19T21:27:52.000Z","date":"2025-08-18","kind":"sale","planned":false,"acquired":false,"shares":19,"price":455.82,"value":8660.58,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $455.65 to $456.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":50121,"source":{"system":"sec-edgar","filing":"0001735276-25-000090","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000090/edgardoc.xml","form_type":"4"}},{"id":1062585,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-08-19T21:27:52.000Z","date":"2025-08-18","kind":"sale","planned":false,"acquired":false,"shares":392,"price":454.84,"value":178297.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $454.58 to $455.55. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":50140,"source":{"system":"sec-edgar","filing":"0001735276-25-000090","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000090/edgardoc.xml","form_type":"4"}},{"id":1062584,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-08-19T21:27:52.000Z","date":"2025-08-18","kind":"sale","planned":false,"acquired":false,"shares":886,"price":454.04,"value":402279.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $453.50 to $454.45. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":50532,"source":{"system":"sec-edgar","filing":"0001735276-25-000090","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000090/edgardoc.xml","form_type":"4"}},{"id":1062583,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-08-19T21:27:52.000Z","date":"2025-08-18","kind":"sale","planned":false,"acquired":false,"shares":536,"price":452.96,"value":242786.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $452.49 to $453.49. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":51418,"source":{"system":"sec-edgar","filing":"0001735276-25-000090","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000090/edgardoc.xml","form_type":"4"}},{"id":1062582,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-08-19T21:27:52.000Z","date":"2025-08-18","kind":"sale","planned":false,"acquired":false,"shares":168,"price":451.99,"value":75934.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $451.48 to $452.48. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":51954,"source":{"system":"sec-edgar","filing":"0001735276-25-000090","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000090/edgardoc.xml","form_type":"4"}},{"id":1062581,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-08-19T21:27:52.000Z","date":"2025-08-18","kind":"sale","planned":false,"acquired":false,"shares":63,"price":450.92,"value":28407.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $450.42 to $451.39. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":52122,"source":{"system":"sec-edgar","filing":"0001735276-25-000090","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000090/edgardoc.xml","form_type":"4"}},{"id":1062580,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-08-19T21:27:52.000Z","date":"2025-08-18","kind":"sale","planned":false,"acquired":false,"shares":147,"price":449.92,"value":66138.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $449.21 to $450.16. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":52185,"source":{"system":"sec-edgar","filing":"0001735276-25-000090","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000090/edgardoc.xml","form_type":"4"}},{"id":1062579,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-08-19T21:27:52.000Z","date":"2025-08-18","kind":"sale","planned":false,"acquired":false,"shares":63,"price":447.98,"value":28222.74,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $447.53 to $448.45. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":52332,"source":{"system":"sec-edgar","filing":"0001735276-25-000090","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000090/edgardoc.xml","form_type":"4"}},{"id":1062578,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-08-19T21:27:52.000Z","date":"2025-08-15","kind":"grant","planned":false,"acquired":true,"shares":4644,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 1, 2024, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of thirty (30) percent of the shares subject to the PSU based on the achievement of a clinical milestone, as determined by The People, Culture and Compensation Committee of the Issuer Board of Directors on August 15, 2025."}],"balance_after":52395,"source":{"system":"sec-edgar","filing":"0001735276-25-000090","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000090/edgardoc.xml","form_type":"4"}},{"id":1101914,"issuer":{"id":7338,"kind":"organization","name":"CervoMed Inc."},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-25T21:01:55.000Z","date":"2025-06-23","kind":"grant","planned":false,"acquired":true,"shares":8100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On June 23, 2025, in connection with the Reporting Person's election to the Issuer's board of directors at its 2025 Annual Meeting of Stockholders, the Reporting Person was granted an option to purchase 8,100 shares of the Issuer's common stock under the Issuer's 2025 Equity Incentive Plan in accordance with the terms of the Issuer's non-employee director compensation policy. The shares of common stock underlying the award will vest on a monthly basis over a one-year period in substantially equal 1/12th increments on the last day of each month beginning on June 30, 2025, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":8100,"derivative":{"exercise_price":6.52,"expiration_date":"2035-06-23","underlying":"Common Stock","underlying_shares":8100},"source":{"system":"sec-edgar","filing":"0001437749-25-021271","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1053691/000143774925021271/rdgdoc.xml","form_type":"4"}},{"id":1223324,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Stock Option  (right to buy)","published_at":"2025-03-05T21:21:25.000Z","date":"2025-03-03","kind":"grant","planned":false,"acquired":true,"shares":9800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The stock option vests as to 25% of the shares on the first anniversary of the grant date and the remaining shares vest in equal installments at the end of each successive three-month period thereafter until the fourth anniversary of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date."}],"balance_after":9800,"derivative":{"exercise_price":243.53,"expiration_date":"2035-03-03","underlying":"Common Stock","underlying_shares":9800},"source":{"system":"sec-edgar","filing":"0001735276-25-000031","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000031/edgardoc.xml","form_type":"4"}},{"id":1223323,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-03-05T21:21:25.000Z","date":"2025-03-03","kind":"sale","planned":false,"acquired":false,"shares":1,"price":248.36,"value":248.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units."}],"balance_after":47751,"source":{"system":"sec-edgar","filing":"0001735276-25-000031","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000031/edgardoc.xml","form_type":"4"}},{"id":1223322,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-03-05T21:21:25.000Z","date":"2025-03-03","kind":"sale","planned":false,"acquired":false,"shares":7,"price":247.35,"value":1731.45,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $247.04 to $247.52. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":47752,"source":{"system":"sec-edgar","filing":"0001735276-25-000031","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000031/edgardoc.xml","form_type":"4"}},{"id":1223321,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-03-05T21:21:25.000Z","date":"2025-03-03","kind":"sale","planned":false,"acquired":false,"shares":77,"price":246.18,"value":18955.86,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $246.00 to $246.71. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":47759,"source":{"system":"sec-edgar","filing":"0001735276-25-000031","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000031/edgardoc.xml","form_type":"4"}},{"id":1223320,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-03-05T21:21:25.000Z","date":"2025-03-03","kind":"sale","planned":false,"acquired":false,"shares":189,"price":245.26,"value":46354.14,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $244.91 to $245.88. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":47836,"source":{"system":"sec-edgar","filing":"0001735276-25-000031","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000031/edgardoc.xml","form_type":"4"}},{"id":1223319,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-03-05T21:21:25.000Z","date":"2025-03-03","kind":"sale","planned":false,"acquired":false,"shares":258,"price":244.41,"value":63057.78,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $243.90 to $244.90. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":48025,"source":{"system":"sec-edgar","filing":"0001735276-25-000031","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000031/edgardoc.xml","form_type":"4"}},{"id":1223318,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-03-05T21:21:25.000Z","date":"2025-03-03","kind":"sale","planned":false,"acquired":false,"shares":382,"price":243.36,"value":92963.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $242.89 to $243.88. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":48283,"source":{"system":"sec-edgar","filing":"0001735276-25-000031","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000031/edgardoc.xml","form_type":"4"}},{"id":1223317,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-03-05T21:21:25.000Z","date":"2025-03-03","kind":"sale","planned":false,"acquired":false,"shares":350,"price":242.37,"value":84829.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $241.87 to $242.86. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":48665,"source":{"system":"sec-edgar","filing":"0001735276-25-000031","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000031/edgardoc.xml","form_type":"4"}},{"id":1223316,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-03-05T21:21:25.000Z","date":"2025-03-03","kind":"grant","planned":false,"acquired":true,"shares":15117,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units (RSUs) granted under the Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest over a three-year period, with one third vesting on each of the first, second and third anniversaries of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The Reporting Person has reported certain prior awards of RSUs in Table II of Form 4.  The total reported in Column 5 includes the 15,117, newly awarded RSUs and 32,634 shares of common stock.  The Reporting Person also holds 1,908 unvested RSUs that were previously reported in Table II."}],"balance_after":49015,"source":{"system":"sec-edgar","filing":"0001735276-25-000031","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000031/edgardoc.xml","form_type":"4"}},{"id":1236448,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2025-03-03T21:31:58.000Z","date":"2025-02-27","kind":"exercise","planned":false,"acquired":false,"shares":1908,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F11","text":"These shares are represented by restricted stock units (RSUs) granted under the Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"On February 27, 2023, the reporting person was granted 5,724 restricted stock units that vest ratably on each of the first, second and third anniversaries of the Grant Date.  On February 27, 2025, the second tranche of restricted stock units from the February 27, 2023 grant vested and was released, as reported on this Form 4."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F12","text":"On February 27, 2023, the reporting person was granted 5,724 restricted stock units that vest ratably on each of the first, second and third anniversaries of the Grant Date.  On February 27, 2025, the second tranche of restricted stock units from the February 27, 2023 grant vested and was released, as reported on this Form 4."}],"balance_after":1908,"derivative":{"underlying":"Common Stock","underlying_shares":1908},"source":{"system":"sec-edgar","filing":"0001735276-25-000022","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000022/edgardoc.xml","form_type":"4"}},{"id":1236447,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-03-03T21:31:58.000Z","date":"2025-02-28","kind":"sale","planned":false,"acquired":false,"shares":59,"price":244.11,"value":14402.49,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $243.90 to $244.32. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":33898,"source":{"system":"sec-edgar","filing":"0001735276-25-000022","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000022/edgardoc.xml","form_type":"4"}},{"id":1236446,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-03-03T21:31:58.000Z","date":"2025-02-28","kind":"sale","planned":false,"acquired":false,"shares":121,"price":243.23,"value":29430.83,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $242.87 to $243.84. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":33957,"source":{"system":"sec-edgar","filing":"0001735276-25-000022","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000022/edgardoc.xml","form_type":"4"}},{"id":1236445,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-03-03T21:31:58.000Z","date":"2025-02-28","kind":"sale","planned":false,"acquired":false,"shares":300,"price":242.44,"value":72732.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $241.86 to $242.86. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":34078,"source":{"system":"sec-edgar","filing":"0001735276-25-000022","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000022/edgardoc.xml","form_type":"4"}},{"id":1236444,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-03-03T21:31:58.000Z","date":"2025-02-28","kind":"sale","planned":false,"acquired":false,"shares":127,"price":241.51,"value":30671.77,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $240.85 to $241.85. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":34378,"source":{"system":"sec-edgar","filing":"0001735276-25-000022","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000022/edgardoc.xml","form_type":"4"}},{"id":1236443,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-03-03T21:31:58.000Z","date":"2025-02-28","kind":"sale","planned":false,"acquired":false,"shares":78,"price":240.32,"value":18744.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $239.82 to $240.79. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":34505,"source":{"system":"sec-edgar","filing":"0001735276-25-000022","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000022/edgardoc.xml","form_type":"4"}},{"id":1236442,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-03-03T21:31:58.000Z","date":"2025-02-28","kind":"sale","planned":false,"acquired":false,"shares":35,"price":239.18,"value":8371.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $238.73 to $239.69. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":34583,"source":{"system":"sec-edgar","filing":"0001735276-25-000022","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000022/edgardoc.xml","form_type":"4"}},{"id":1236441,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-03-03T21:31:58.000Z","date":"2025-02-28","kind":"sale","planned":false,"acquired":false,"shares":34,"price":238.33,"value":8103.22,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $237.72 to $238.72. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":34618,"source":{"system":"sec-edgar","filing":"0001735276-25-000022","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000022/edgardoc.xml","form_type":"4"}},{"id":1236440,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-03-03T21:31:58.000Z","date":"2025-02-28","kind":"sale","planned":false,"acquired":false,"shares":42,"price":236.51,"value":9933.42,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $236.50 to $237.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":34652,"source":{"system":"sec-edgar","filing":"0001735276-25-000022","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000022/edgardoc.xml","form_type":"4"}},{"id":1236439,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-03-03T21:31:58.000Z","date":"2025-02-27","kind":"exercise","planned":false,"acquired":true,"shares":1908,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":34694,"source":{"system":"sec-edgar","filing":"0001735276-25-000022","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000022/edgardoc.xml","form_type":"4"}},{"id":1264471,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-18T21:47:57.000Z","date":"2025-02-14","kind":"sale","planned":false,"acquired":false,"shares":20,"price":264.87,"value":5297.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form."}],"balance_after":32786,"source":{"system":"sec-edgar","filing":"0001735276-25-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000011/edgardoc.xml","form_type":"4"}},{"id":1264470,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-18T21:47:57.000Z","date":"2025-02-14","kind":"sale","planned":false,"acquired":false,"shares":17,"price":263.33,"value":4476.61,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form."}],"balance_after":32806,"source":{"system":"sec-edgar","filing":"0001735276-25-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000011/edgardoc.xml","form_type":"4"}},{"id":1264469,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-18T21:47:57.000Z","date":"2025-02-14","kind":"sale","planned":false,"acquired":false,"shares":37,"price":261.45,"value":9673.65,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $261.42  to $261.47. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":32823,"source":{"system":"sec-edgar","filing":"0001735276-25-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000011/edgardoc.xml","form_type":"4"}},{"id":1264468,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-18T21:47:57.000Z","date":"2025-02-14","kind":"sale","planned":false,"acquired":false,"shares":30,"price":260.57,"value":7817.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $260.31  to $260.96. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":32860,"source":{"system":"sec-edgar","filing":"0001735276-25-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000011/edgardoc.xml","form_type":"4"}},{"id":1264467,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-18T21:47:57.000Z","date":"2025-02-14","kind":"sale","planned":false,"acquired":false,"shares":17,"price":259.72,"value":4415.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $259.21  to $260.14. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":32890,"source":{"system":"sec-edgar","filing":"0001735276-25-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000011/edgardoc.xml","form_type":"4"}},{"id":1264466,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-18T21:47:57.000Z","date":"2025-02-14","kind":"sale","planned":false,"acquired":false,"shares":47,"price":258.07,"value":12129.29,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $257.86  to $258.44. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":32907,"source":{"system":"sec-edgar","filing":"0001735276-25-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000011/edgardoc.xml","form_type":"4"}},{"id":1264465,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-18T21:47:57.000Z","date":"2025-02-14","kind":"sale","planned":false,"acquired":false,"shares":37,"price":257.51,"value":9527.87,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $257.05  to $257.78. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":32954,"source":{"system":"sec-edgar","filing":"0001735276-25-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000011/edgardoc.xml","form_type":"4"}},{"id":1264464,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-18T21:47:57.000Z","date":"2025-02-14","kind":"sale","planned":false,"acquired":false,"shares":78,"price":256.29,"value":19990.62,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $256.01  to $256.84. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":32991,"source":{"system":"sec-edgar","filing":"0001735276-25-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000011/edgardoc.xml","form_type":"4"}},{"id":1264463,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-18T21:47:57.000Z","date":"2025-02-14","kind":"sale","planned":false,"acquired":false,"shares":68,"price":255.56,"value":17378.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $254.99  to $255.97. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":33069,"source":{"system":"sec-edgar","filing":"0001735276-25-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000011/edgardoc.xml","form_type":"4"}},{"id":1264462,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":39782,"kind":"person","name":"Poulton Jeffrey V.","position":1,"cik":"0001782962","reported_name":"Poulton Jeffrey V.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-18T21:47:57.000Z","date":"2025-02-14","kind":"sale","planned":false,"acquired":false,"shares":160,"price":254.35,"value":40696.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $253.96  to $254.93. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":33137,"source":{"system":"sec-edgar","filing":"0001735276-25-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000011/edgardoc.xml","form_type":"4"}}],"next_cursor":"2025-02-18T21:47:57.000000Z,1264462"}